Vortioxetine: a comprehensive update on a new-generation antidepressant
- 1 January 2021
- journal article
- editorial
- Published by Kare Publishing in Dusunen Adam the Journal of Psychiatry and Neurological Sciences
- Vol. 34 (1), 1-13
- https://doi.org/10.14744/dajpns.2021.00115
Abstract
No abstract availableThis publication has 85 references indexed in Scilit:
- A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorderInternational Journal of Neuropsychopharmacology, 2011
- Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive DisorderJournal of Medicinal Chemistry, 2011
- An investigation of EEG, genetic and cognitive markers of treatment response to antidepressant medication in patients with major depressive disorder: A pilot studyJournal of Affective Disorders, 2011
- Frontocingulate Dysfunction in Depression: Toward Biomarkers of Treatment ResponseNeuropsychopharmacology, 2010
- Association between depression severity and neurocognitive function in major depressive disorder: A review and synthesis.Neuropsychology, 2010
- A meta-analysis of depression severity and cognitive functionJournal of Affective Disorders, 2009
- Effects of selective serotonin reuptake and dual serotonergic–noradrenergic reuptake treatments on memory and mental processing speed in patients with major depressive disorderJournal of Psychiatric Research, 2009
- Mediators of the association between depression and role functioningActa Psychiatrica Scandinavica, 2008
- Implications of the DSM's emphasis on sadness and anhedonia in major depressive disorderPsychiatry Research, 2008
- The assessment of anhedonia in clinical and non-clinical populations: Further validation of the Snaith–Hamilton Pleasure Scale (SHAPS)Journal of Affective Disorders, 2007